An interventional study of Placebo and Phosphatidylserine-Omega3 in Attention Deficit Hyperactivity Disorder (ADHD) and ADHD, sponsored by Çağlar Charles Daniel Jaicks. Completed at 1 site in Turkey (Türkiye). Open to participants aged 10 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Çağlar Charles Daniel Jaicks · Not applicable, Interventional, and Treatment
This study aimed to evaluate the effects of different phosphatidylserine (PS) formulations, with or without docosahexaenoic acid (DHA), on cognitive performance in children diagnosed with attention-deficit/hyperactivity disorder (ADHD) or presenting with clinically significant subthreshold ADHD symptoms.
A total of 45 medication-naïve children aged 10-14 years were randomly assigned to one of four groups: placebo, PS capsule (PS + DHA), PS sachet (PS without DHA), or PS Plus capsule (higher-dose PS + DHA). The intervention period was eight weeks.
Cognitive performance was assessed at baseline and after the intervention using the MOXO continuous performance test and the Stroop test. The study aimed to compare the effects of different PS formulations on attention, impulsivity, hyperactivity, and executive function.
This prospective, randomized, placebo-controlled clinical trial was conducted to investigate the cognitive effects of phosphatidylserine-based nutritional supplementation in children with ADHD or clinically significant subthreshold ADHD symptoms.
Participants were medication-naïve children aged 10-14 years who were diagnosed based on DSM-5 criteria or clinical evaluation supported by standardized rating scales. Eligible participants were randomly assigned in a 1:1:1:1 ratio to one of four groups: placebo, PS capsule (100 mg phosphatidylserine + 17.78 mg DHA), PS sachet (117.78 mg phosphatidylserine without DHA), or PS Plus capsule (150 mg phosphatidylserine + 26.67 mg DHA).
All participants received their assigned intervention once daily for eight weeks. Cognitive outcomes were assessed using the MOXO continuous performance test (MOXO d-CPT), which evaluates attention, impulsivity, timing, and hyperactivity, and the Stroop test, which measures executive function, inhibitory control, and cognitive flexibility.
The primary objective of the study was to compare changes in cognitive performance across the different intervention groups. The study was conducted in a single-center clinical setting, and all assessments were performed under standardized conditions.
The findings were intended to provide insight into the dose- and formulation-dependent cognitive effects of phosphatidylserine supplementation, particularly in combination with DHA, in pediatric ADHD populations.
1,514 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 255 are open to participants now.
This study's enrollment of 45 is below the median of 72 across 1,207 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Browse Attention Deficit Disorder with Hyperactivity studies →This is the only study on the registry with Çağlar Charles Daniel Jaicks as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants received placebo once daily for 8 weeks.
Other: Placebo
Participants received phosphatidylserine capsule with DHA once daily for 8 weeks.
Dietary Supplement: Phosphatidylserine-Omega3
Participants received phosphatidylserine sachet without DHA once daily for 8 weeks.
Dietary Supplement: Phosphatidylserine-Omega3
Participants received higher-dose phosphatidylserine with DHA once daily for 8 weeks.
Dietary Supplement: DHA Omega-3
Placebo formulation identical in appearance and administration to active supplements.
Capsule containing 100 mg phosphatidylserine and 17.78 mg DHA administered once daily for 8 weeks.
Also known as: Phosphatidylserine Capsule
Sachet formulation containing 117.78 mg phosphatidylserine without DHA administered once daily for 8 weeks.
Also known as: Phosphatidylserine Sachet
Capsule containing 150 mg phosphatidylserine and 26.67 mg DHA administered once daily for 8 weeks.
Also known as: Capsule containing 150 mg phosphatidylserine and 26.67 mg DHA administered once daily for 8 weeks.
Change in Attention and Executive Function Scores (MOXO and Stroop Tests)
Change from baseline to 8 weeks in cognitive performance assessed using the MOXO continuous performance test (attention, impulsivity, timing, and hyperactivity domains) and the Stroop test (reaction time, error rates, and correction counts).
Time frame: Baseline and 8 weeks
Change in MOXO Attention Score
Change from baseline to 8 weeks in attention performance measured by MOXO d-CPT.
Time frame: Baseline and 8 weeks
Change in MOXO Impulsivity Score
Change from baseline to 8 weeks in impulsivity measured by MOXO d-CPT.
Time frame: Baseline and 8 weeks
Change in MOXO Hyperactivity Score
Change from baseline to 8 weeks in hyperactivity measured by MOXO d-CPT.
Time frame: Baseline and 8 weeks
Change in Stroop Reaction Time
Change from baseline to 8 weeks in reaction time measured by the Stroop test.
Time frame: Baseline and 8 weeks
Change in Stroop Error Scores
Change from baseline to 8 weeks in error rates measured by the Stroop test.
Time frame: Baseline and 8 weeks
Change in Stroop Correction Counts
Change from baseline to 8 weeks in correction counts measured by the Stroop test.
Time frame: Baseline and 8 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity→